Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Stocks that are trending today. Stéphane Bancel, CEO of Moderna , said: "We remain focused on our strategy to build a large ...
Investor's Business Daily on MSN
Moderna stock gets healthy relative strength rating jump
On Tuesday, Moderna MRNA got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73. This exclusive rating ...
Elie Honig, a former federal and state prosecutor and CNN senior legal analyst, has closely followed the turmoil in Chicago ...
Zacks.com on MSN
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...
Asian shares are trading mixed after Wall Street pulled back from its recent records and as political uncertainty brewed in ...
Wall Street pulled back from its records on Tuesday following a mixed start to the latest profit reporting season for big U.S ...
Wall Street pulled back from its records on Tuesday following a mixed start to the latest profit reporting season for big U.S ...
Wall Street pulled back from its records following a mixed start to the latest profit reporting season for big U.S. companies ...
Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback